Patents Represented by Attorney Serena Farquharson-Torres
  • Patent number: 8129408
    Abstract: The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: March 6, 2012
    Assignee: Aventisub II Inc.
    Inventors: Thomas T Ortyl, Paul F Skultety, Kristen C Mitchell, Deepak S Phadke, Faraneh Attarchi, Marguerite L Pierce, Aaron W Schoeneman, Joseph M Schnitz
  • Patent number: 8008340
    Abstract: A method for inhibiting casein kinase I? activity, comprising administering to said patient a therapeutically effective amount of a compound of formula I. its stereoisomer, enantiomer, racemate, tautomer or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: August 30, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventor: William Arthur Metz, Jr.
  • Patent number: 7947701
    Abstract: The invention relates to dual molecule compounds containing a peroxide derivative, to processes for the synthesis of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment and prevention of malaria comprising administering such compounds and such pharmaceutical compositions.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: May 24, 2011
    Assignee: Sanofi-Aventis
    Inventors: Jérôme Cazelles, Frédéric Cosledan, Bernard Meunier, Alain Pellet
  • Patent number: 7919628
    Abstract: The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: April 5, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stephanie Hachtel, Juergen Dedio, Holger Heitsch, Werngard Czechtizky, Sven Grueneberg, Stephen J. Shimshock, Raymond W. Kosley, Jr., Carolina L. Lanter, Hui Li, Rosy Sher, Aleksandra Weichsel
  • Patent number: 7872034
    Abstract: The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: January 18, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Christian Stapper, Stefanie Keil, Heiner Glombik, Eugen Falk, Jochen Goerlitzer, Dirk Gretzke, Hans-Ludwig Schaefer, Wolfgang Wendler
  • Patent number: 7863280
    Abstract: This invention relates to compounds of formula (I), wherein R1 and R3 independently represent fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; R2 represents hydrogen, fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; X represents O, S, NH or N(C1-C3-alkyl); and Ar represents an unsubstituted or at least monosubstituted aryl or heteroaryl. Said compounds are inhibitors of poly(ADP-ribose) polymerase (PARP), and may be used for the treatment of a variety of disorders.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: January 4, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn
  • Patent number: 7858824
    Abstract: The present invention relates to compounds of formula (IIIo): in which n is an integer from 1 to 5; Ao represents a partially saturated carbonaceous bi- or tricycle; it also relates to their salts, solvates, N-oxides, the pharmaceutical compositions containing them, a method for their preparation and synthesis intermediates in this method.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: December 28, 2010
    Assignee: sanofi-aventis
    Inventors: Marco Baroni, Bernard Bourrie, Rosanna Cardamone, Pierre Casellas
  • Patent number: 7838528
    Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed and comprise novel substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are hereinafter defined. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds. Particular blood glucose disorders treatable thereby include type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerotic diseases and the like.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: November 23, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Lothar Schwink, Holger Wagner, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7827989
    Abstract: A rotatably actuated counter is disclosed. The counter includes a ratchet driven unit wheel nested within a tens wheel. Each wheel has a radial face displaying counting indicia. The tens wheel is transparent, allowing the indicia on the unit wheel to be viewed adjacent to the indicia on the tens wheel to provide a total count. A slave wheel is positioned between the unit and tens wheels. A gear on one face of the slave wheel engages gear teeth on the tens wheel. A Geneva mechanism on the other face is engaged by a foot on the unit wheel once per rotation. The wheels are rotatably mounted within a housing having a sidewall with a window through which the count indicia may be viewed. The unit wheel rotates in ten increments and then rotates the tens wheel through one increment by engaging and rotating the slave wheel.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: November 9, 2010
    Assignee: Aventis Pharma Limited
    Inventors: Noel Butterworth, Stephen John Minshull, Simon Paul Wells, Duncan Grant Young
  • Patent number: 7825264
    Abstract: The invention relates to compounds of formula I in which A, R1, R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 2, 2010
    Assignee: sanofi-aventis
    Inventors: Joachim Brendel, Heinrich Christian Englert, Stefan Peukert, Klaus Wirth, Michael Wagner, Jean-Marie Ruxer, Fabienne Pilorge
  • Patent number: 7799922
    Abstract: The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II?), (III?), (IV?), (V?), (VI?), (VII?), (VIII?) and (XIII?) and their preparation.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: September 21, 2010
    Assignee: sanofi-aventis
    Inventors: Peter Aranyi, Sandor Batori, Geza Timari, Kinga Boer, Zoltan Kapui, Endre Mikus, Katalin Urban-Szabo, Katalin Gerber, Judit Vargane Szeredi, Michel Finet
  • Patent number: 7795445
    Abstract: The present invention comprises the substituted 2-aminoalkylthiobenzimidazoles of formula I wherein R1-R5 and R11-R16 are hereinafter defined. These compounds, their derivatives and the pharmaceutically acceptable salts thereof are useful in the reduction of elevated blood sugar levels and are therefore useful in the treatment of hyperglycemia, diabetes, atherosclerosis and other blood sugar disorders. These compounds are particularly suitable in the treatment of type-2 diabetes.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: September 14, 2010
    Assignee: sanofi-aventis
    Inventors: Elisabeth Defossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7795278
    Abstract: This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: September 14, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn
  • Patent number: 7781455
    Abstract: Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: August 24, 2010
    Assignee: sanofi-aventis
    Inventors: Péter Arányi, László Balázs, Imre Bata, Sándor Bátori, Éva Boronkay, Zoltán Kapui, Edit Susán, Tibor Szabó, Lajos T. Nagy, Katalin Urbán-Szabó, Márton Varga
  • Patent number: 7700773
    Abstract: In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Alan K. Mallams, Vincent S. Madison, Kamil Paruch
  • Patent number: 7488752
    Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein z,1 represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A, B, G, M, X, J, n, Het, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: February 10, 2009
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia, Keith A. Eagen
  • Patent number: 7354922
    Abstract: A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: April 8, 2008
    Assignee: Schering Corporation
    Inventors: Dong Xiao, Anandan Palani, Cheng Wang, Hon-Chung Tsui, Xianhai Huang, Sapna S. Shah, Ashwin U. Rao, Xiao Chen, Sunil Paliwal, Neng-Yang Shih
  • Patent number: 7342041
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: March 11, 2008
    Assignee: Schering Corporation
    Inventors: F. George Njoroge, Srikanth Venkatraman, Ashok Arasappan, Francisco Velazquez, Viyyoor M. Girijavallabhan
  • Patent number: 7253160
    Abstract: The present invention discloses novel depeptidized compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: August 7, 2007
    Assignee: Schering Corporation
    Inventors: F. George Njoroge, Srikanth Venkatraman, Viyyoor M. Girijavallabhan
  • Patent number: 7173057
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: February 6, 2007
    Assignee: Schering Corporation
    Inventors: Kevin X. Chen, F. George Njoroge, Mousumi Sannigrahi, Latha G. Nair, Weiying Yang, Bancha Vibulbhan, Srikanth Venkatraman, Ashok Arasappan, Stephane L. Bogen, Frank Bennett, Viyyoor M. Girijavallabhan